| scholarly article | Q13442814 |
| P356 | DOI | 10.1002/PROS.1129 |
| P698 | PubMed publication ID | 11582594 |
| P2093 | author name string | Matzkin H | |
| Bartsch G | |||
| Klocker H | |||
| Zisapel N | |||
| Culig Z | |||
| Levy-Rimler G | |||
| Lupowitz Z | |||
| Rimler A | |||
| P2860 | cites work | Pineal Melatonin: Cell Biology of Its Synthesis and of Its Physiological Interactions* | Q22306227 |
| A modification of the Lowry procedure to simplify protein determination in membrane and lipoprotein samples | Q29615292 | ||
| Clinical aspects of the melatonin action: impact of development, aging, and puberty, involvement of melatonin in psychiatric disease and importance of neuroimmunoendocrine interactions | Q40839596 | ||
| Hormonal interactions in human prostate tumor LNCaP cells | Q40958828 | ||
| Androgen receptor: an overview | Q41000439 | ||
| Regulation of proliferation and production of prostate-specific antigen in androgen-sensitive prostatic cancer cells, LNCaP, by dihydrotestosterone | Q41378207 | ||
| Cell nucleus and DNA fragmentation are not required for apoptosis | Q41441006 | ||
| The influence of hormonal therapy on survival of men with advanced prostatic cancer. | Q41457056 | ||
| Antipeptide antibodies to two distinct regions of the androgen receptor localize the receptor protein to the nuclei of target cells in the rat and human prostate | Q41735497 | ||
| Expression, structure, and function of androgen receptor in advanced prostatic carcinoma. | Q41736561 | ||
| Switch from antagonist to agonist of the androgen receptor bicalutamide is associated with prostate tumour progression in a new model system | Q41827081 | ||
| N-(2,4-dinitrophenyl)-5-methoxytryptamine, a novel melatonin antagonist: effects on sexual maturation of the male and female rat and on oestrous cycles of the female rat [corrected] | Q41854862 | ||
| Cytoplasmic localization and the choice of ligand determine aggregate formation by androgen receptor with amplified polyglutamine stretch | Q41860888 | ||
| Immunohistochemical Localization of the Androgen Receptor in Rat and Human Tissues* | Q48857175 | ||
| Effects of Melatonin on Changes Induced by Castration and Testosterone in Sexual Structures of Male Rats | Q48878511 | ||
| Functional melatonin receptors in human prostate epithelial cells. | Q50750858 | ||
| A C619Y mutation in the human androgen receptor causes inactivation and mislocalization of the receptor with concomitant sequestration of SRC-1 (steroid receptor coactivator 1) | Q73273852 | ||
| Evidence for a local action of melatonin on the rat prostate | Q74216494 | ||
| Estrogen receptor transactivation in MCF-7 breast cancer cells by melatonin and growth factors | Q77179702 | ||
| Melatonin receptors in PC3 human prostate tumor cells | Q77788314 | ||
| P433 | issue | 2 | |
| P921 | main subject | melatonin | Q180912 |
| P304 | page(s) | 145-154 | |
| P577 | publication date | 2001-10-01 | |
| P1433 | published in | The Prostate | Q7758608 |
| P1476 | title | Melatonin elicits nuclear exclusion of the human androgen receptor and attenuates its activity | |
| P478 | volume | 49 |
| Q53907010 | Androgen receptor outwits prostate cancer drugs. |
| Q31031948 | Cancer incidence among male military and civil pilots and flight attendants: an analysis on published data |
| Q42480374 | Coexpression of MT1 and RORalpha1 melatonin receptors in the Syrian hamster Harderian gland. |
| Q40324169 | Differential effects of melatonin and its downstream effector PKCalpha on subcellular localization of RGS proteins |
| Q38229317 | Expression and putative functions of melatonin receptors in malignant cells and tissues |
| Q39538005 | Functional interplay between melatonin receptor-mediated antiproliferative signaling and androgen receptor signaling in human prostate epithelial cells: potential implications for therapeutic strategies against prostate cancer. |
| Q40148180 | Gi and RGS proteins provide biochemical control of androgen receptor nuclear exclusion |
| Q35947279 | Influence of Melatonin on the Proliferative and Apoptotic Responses of the Prostate under Normal and Hyperglycemic Conditions. |
| Q39472810 | Intracellular redox state as determinant for melatonin antiproliferative vs cytotoxic effects in cancer cells |
| Q46205660 | Management of metastatic androgeno-independent prostate cancer |
| Q41660894 | Melatonin and Hippo Pathway: Is There Existing Cross-Talk? |
| Q44059675 | Melatonin and prostate cancer cell proliferation: interplay with castration, epidermal growth factor, and androgen sensitivity |
| Q40513840 | Melatonin reduces prostate cancer cell growth leading to neuroendocrine differentiation via a receptor and PKA independent mechanism |
| Q33624824 | Melatonin, a Full Service Anti-Cancer Agent: Inhibition of Initiation, Progression and Metastasis |
| Q58587207 | Melatonin: An Anti-Tumor Agent in Hormone-Dependent Cancers |
| Q33276580 | Molecular staging of prostate cancer in the year 2007. |
| Q40717180 | Nuclear exclusion of the androgen receptor by melatonin |
| Q36021305 | Prostate cancer mortality risk in relation to working underground in the Wismut cohort study of German uranium miners, 1970-2003. |
| Q40173621 | Signaling mechanisms of melatonin in antiproliferation of hormone-refractory 22Rv1 human prostate cancer cells: implications for prostate cancer chemoprevention |
| Q36872043 | Towards rational and evidence-based use of melatonin in prostate cancer prevention and treatment. |
| Q28077467 | WOMEN IN CANCER THEMATIC REVIEW: Circadian rhythmicity and the influence of 'clock' genes on prostate cancer |
Search more.